Alzheimer's disease and chronic periodontitis: Is there an association?

Geriatrics and Gerontology International

Volumn 15, Issue 4, 2015, Pages 391-404

  Gaur, Sumit ^a   Agnihotri, Rupali ^a  

^a MANIPAL COLLEGE OF DENTAL SCIENCES   (India)

Author keywords

Alzheimer's disease; Chronic periodontitis; Dementia

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CYTOKINE RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; PRESENILIN 2; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANEUPLOIDY; APOPTOSIS; BRAIN MITOCHONDRION; CEREBROVASCULAR DISEASE; CHRONIC PERIODONTITIS; COGNITIVE DEFECT; CONSERVATIVE TREATMENT; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; LONG TERM EXPOSURE; MEDIATOR RELEASE; META ANALYSIS (TOPIC); MOUTH FLORA; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PERIODONTAL DISEASE; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SCREENING; TANNERELLA FORSYTHIA; TREPONEMA DENTICOLA; VIRUS INFECTION;

EID: 84965106861     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12425     Document Type: Review

References (133)

1. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med [serial on the internet]. 2009; 7: [about 4 p.]. [Cited 5 May 2014.] Available from URL: http://www.biomedcentral.com/1741-7015/7/7.
2. Galimberti D, Scarpini E. Progress in Alzheimer's disease research in the last year. J Neurol 2013; 260: 1936-1941.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-191.
4. Rogers J. The inflammatory response in Alzheimer's disease. J Periodontol 2008; 79 (8 Suppl): 1535-1543.
5. Kamer AR, Craig RG, Dasanayake AP, Brys M, Glodzik-Sobanska L, de Leon MJ. Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement 2008; 4: 242-250.
6. Watts A, Crimmins EM, Gatz M. Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease. Neuropsychiatr Dis Treat 2008; 4: 865-876.
7. Petersen PE, Kandleman D, Arpin S, Ogawa H. Global oral health of older people- call for public health action. Community Dent Health 2010; 27 (4 Suppl 2): 257-267.
8. Holmes C, Cotterell D. Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2009; 23: 993-1002.
9. Kamer AR, Morse DE, Holm-Pedersen P, Mortensen EL, Avlund K. Periodontal inflammation in relation to cognitive function in an older adult Danish population. J Alzheimers Dis 2012; 28: 613-624.
10. Batty GD, Li Q, Huxley R etal. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) Trial. Eur Psychiatry 2013; 28: 49-52.
11. Stein PS, Desrosiers M, Donegan SJ, Yepes JF, Kryscio RJ. Tooth loss, dementia and neuropathology in the Nun Study. J Am Dent Assoc 2007; 138: 1314-1322.
12. Kaye EK, Valencia A, Baba N, Spiro A 3rd, Dietrich T, Garcia RI. Tooth loss and periodontal disease predict poor cognitive function in older men. J Am Geriatr Soc 2010; 58: 713-718.
13. Stewart R, Sabbah W, Tsakos G, D'Aiuto F, Watt RG. Oral health and cognitive function in the Third National Health and Nutrition Examination Survey (NHANES III). Psychosom Med 2008; 70: 936-941.
14. Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging 2007; 2: 347-359.
15. Akiyama H, Barger S, Barnum S etal. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
16. Levy-Lahad E, Wasco W, Poorkaj P etal. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-977.
17. Sherrington R, Rogaev EI, Liang Y etal. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-760.
18. Laskowitz DT, Goel S, Bennett ER, Matthew WD. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 1997; 76: 70-74.
19. Holtzman DM, Bales KR, Wu S etal. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999; 103: R15-R21.
20. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999; 398: 513-517.
21. Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma secretase activity and amyloid beta-protein generation. J Biol Chem 2000; 275: 3173-3178.
22. Seeman P, Seeman N. Alzheimer's disease: β-amyloid plaque formation in human brain. Synapse 2011; 65: 1289-1297.
23. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 2004; 63: 8-20.
24. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.
25. El Khoury JB, Moore KJ, Means TK etal. CD36 mediates the innate host response to beta-amyloid. J Exp Med 2003; 197: 1657-1666.
26. Lorton D, Schaller J, Lala A, De Nardin E. Chemotactic like receptors and Abeta peptide induced responses in Alzheimer's disease. Neurobiol Aging 2000; 21: 463-473.
27. Yan SD, Chen X, Fu J etal. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691.
28. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 2001; 39: 333-340.
29. Lue LF, Rydel R, Brigham EF etal. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001; 35: 72-79.
30. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM. The NF-kappaB/Rel family of proteins mediates A beta-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 1998; 57: 63-72.
31. Meda L, Cassatella MA, Szendrei GI etal. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995; 374: 647-650.
32. Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A 1998; 95: 5795-5800.
33. Meda L, Bernasconi S, Bonaiuto C etal. Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP- 1/JE in monocytes and microglial cells. J Immunol 1996; 157: 1213-1218.
34. Marques F, Sousa JC, Sousa N, Palha JA. Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener [serial on the internet]. 2013; 8: [about 9 p.]. [Cited 10 May 2014.] Available from URL: http://www.molecularneurodegeneration.com/content/8/1/38.
35. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS [serial on the internet]. 2011 8: [about9 p.]. [Cited 20 May 2014.] Available from URL: http://www.fluidsbarrierscns.com/content/8/1/4.
36. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B. Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol 2011; 37: 24-39.
37. Dunn AJ. Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp Ther 1992; 261: 964-969.
38. Wong ML, Bongiorno PB, al-Shekhlee A, Esposito A, Khatri P, Licinio J. IL-1 beta, IL-1 receptor type I and iNOS gene expression in rat brain vasculature and perivascular areas. Neuroreport 1996; 7: 2445-2448.
39. Anthony DC, Bolton SJ, Fearn S, Perry VH. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brainbarrier permeability in rats. Brain 1997; 120: 435-444.
40. Maier SF, Goehler LE, Fleshner M, Watkins LR. The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci 1998; 840: 289-300.
41. Dantzer R, Bluthé RM, Layé S, Bret-Dibat JL, Parnet P, Kelley KW. Cytokines and sickness behaviour. Ann N Y Acad Sci 1998; 840: 586-590.
42. Goehler LE, Gaykema RP, Nguyen KT etal. Interleukin-1beta in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems? J Neurosci 1999; 19: 2799-2806.
43. Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularisation. J Neurosci 1988; 8: 2485-2490.
44. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A 1989; 86: 6348-6352.
45. Jeohn GH, Kong LY, Wilson B, Hudson P, Hong JS. Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol 1998; 85: 1-10.
46. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002; 50: 2041-2056.
47. Grabe HJ, Schwahn C, Völzke H etal. Tooth loss and cognitive impairment. J Clin Periodontol 2009; 36: 550-557.
48. Kamer AR, Craig RG, Pirraglia E etal. TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. J Neuroimmunol 2009; 216: 92-97.
49. Noble JM, Borrell LN, Papapanou PN, Elkind MS, Scarmeas N, Wright CB. Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III. J Neurol Neurosurg Psychiatry 2009; 80: 1206-1211.
50. Okamoto N, Morikawa M, Okamoto K etal. Relationship of tooth loss to mild memory impairment and cognitive impairment: findings from the Fujiwara-Kyo study. Behav Brain Funct [serial on the internet]. 2010; 6: [about8 p]. [Cited 22 May 2014.] Available from URL: http://www.behavioralandbrainfunctions.com/content/6/1/77.
51. Sparks Stein P, Steffen MJ, Smith C etal. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement 2012; 8: 196-203.
52. Minn YK, Suk SH, Park H etal. Tooth loss is associated with brain white matter change and silent infarction among adults without dementia and stroke. J Korean Med Sci 2013; 28: 929-933.
53. Saito Y, Sugawara N, Yasui-Furukori N, Takahashi I, Nakaji S, Kimura H. Cognitive function and number of teeth in a community-dwelling population in Japan. Ann Gen Psychiatry [serial on the internet]. 2013; 12: [about 6 p.]. [Cited 24 May 2014.] Available from URL: http://www.annals-general-psychiatry.com/content/12/1/20.
54. Oue H, Miyamoto Y, Okada S etal. Tooth loss induces memory impairment and neuronal cell loss in APP transgenic mice. Behav Brain Res 2013; 252: 318-325.
55. Kubota T, Maruyama S, Abe D etal. Amyloid beta (A4) precursor protein expression in human periodontitis-affected gingival tissues. Arch Oral Biol 2014; 59: 586-594.
56. Stein PS, Scheff S, Dawson DR. Alzheimer's disease and periodontal disease: mechanisms underlying a potential bi-directional relationship. Grand Rounds Oral Syst Med 2006; 1: 14-24.
57. Ghezzi EM, Ship JA. Dementia and Oral health. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 2-5.
58. Chalmers JM, Carter KD, Spencer AJ. Oral diseases and conditions in community-living older adults with and without dementia. Spec Care Dentist 2003; 23: 7-17.
59. Henriksen BM, Engedal K, Axéll T. Cognitive impairment is associated with poor oral health in individuals in long-term care. Oral Health Prev Dent 2005; 3: 203-207.
60. Yamazaki K, Wakabayashi N, Kobayashi T, Suzuki T. Effect of tooth loss on spatial memory and trkB-mRNA levels in rats. Hippocampus 2008; 18: 542-547.
61. Makiura T, Ikeda Y, Hirai T, Terasawa H, Hamaue N, Minami M. Influence of diet and occlusal support on learning memory in rats behavioral and biochemical studies. Res Commun Mol Pathol Pharmacol 2000; 107: 269-277.
62. Kato T, Usami T, Noda Y, Hasegawa M, Ueda M, Nabeshima T. The effect of the loss of molar teeth on spatial memory and acetylcholine release from the parietal cortex in aged rats. Behav Brain Res 1997; 83: 239-242.
63. Schmand B, Smit J, Lindeboom J etal. Low education is a genuine risk factor for accelerated memory decline and dementia. J Clin Epidemiol 1997; 50: 1025-1033.
64. Borrell LN, Crawford ND. Socioeconomic position indicators and periodontitis: examining the evidence. Periodontol 2000 2012; 58: 69-83.
65. Armstrong RA. What causes alzheimer's disease? Folia Neuropathol 2013; 51: 169-188.
66. Singhrao SK, Harding A, Simmons T, Robinson S, Kesavalu L, Crean S. Oral inflammation, tooth loss, risk factors, and association with progression of Alzheimer's disease. J Alzheimers Dis 2014; 42: 723-737.
67. Balin BJ, Appelt DM. Role of infection in Alzheimer's disease. J Am Osteopath Assoc 2001; 101: S1-S6.
68. Strandberg TE, Pitkala KH, Linnavuori KH, Tilvis RS. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke 2003; 34: 2126-2131.
69. Gieffers J, Reusche E, Solbach W, Maass M. Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients. J Clin Microbiol 2000; 38: 881-882.
70. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett 2007; 429: 95-100.
71. Pyles RB. The association of herpes simplex virus and Alzheimer's disease: a potential synthesis of genetic and environmental factors. Herpes 2001; 8: 64-68.
72. Itzhaki RF, Wozniak MA. Viral infection and cognitive decline. J Am Geriatr Soc 2007; 55: 131.
73. Slots J. Oral viral infections of adults. Periodontol 2000 2009; 49: 60-86.
74. Slots J. Herpesviral-bacterial interactions in periodontal diseases. Periodontol 2000 2010; 52: 117-140.
75. Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol 2002; 17: 113-118.
76. Miklossy J. Alzheimer's disease-a spirochetosis? Neuroreport 1993; 4: 841-848.
77. Hammond RR, Gage FH, Terry RD. Alzheimer's disease and spirochetes; a questionable relationship. Neuroreport 1993; 4: 840.
78. McLaughlin R, Kin NM, Chen MF, Nair NP, Chan EC. Alzheimer's disease may not be a spirochetosis. Neuroreport 1999; 10: 1489-1491.
79. Poole S, Singhrao SK, Chukkapalli S etal. Active Invasion of Porphyromonas gingivalis and Infection-Induced Complement Activation in ApoE-/- Mice Brains. J Alzheimers Dis 2014. doi: 10.3233/JAD-140315.
80. Rivest S, Lacroix S, Vallières L, Nadeau S, Zhang J, Laflamme N. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000; 223: 22-38.
81. Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J Alzheimers Dis 2013; 36: 665-677.
82. Kim J, Amar S. Periodontal disease and systemic conditions: a bidirectional relationship. Odontology 2006; 94: 10-21.
83. Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, andneuropathic pain. Mediators Inflamm [serial on the internet]. 2013; 2013: [about 20 p.]. [Cited 27 Sep 2014.] Available from URL: http://www.hindawi.com/journals/mi/2013/480739/cta/.
84. Tan ZS, Beiser AS, Vasan RS etal. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007; 68: 1902-1908.
85. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002; 59: 371-378.
86. Yaffe K, Lindquist K, Penninx BW etal. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61: 76-80.
87. Engelhart MJ, Geerlings MI, Meijer J etal. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol 2004; 61: 668-672.
88. Li K, Dai D, Zhao B etal. Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transm 2010; 117: 97-104.
89. Daborg J, von Otter M, Sjölander A etal. Association of the RAGE G82S polymorphism with Alzheimer's disease. J Neural Transm 2010; 117: 861-867.
90. Nicoll JA, Mrak RE, Graham DI etal. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000; 47: 365-368.
91. Kornman KS, di Giovine FS. Genetic variations in cytokine expression: a risk factor for severity of adult periodontitis. Ann Periodontol 1998; 3: 327-338.
92. Kornman KS, Crane A, Wang HY etal. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24: 72-77.
93. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001; 58: 1790-1792.
94. Grimaldi LM, Casadei VM, Ferri C etal. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 2000; 47: 361-365.
95. Karimbux NY, Saraiya VM, Elangovan S etal. Interleukin-1 gene polymorphisms and chronic periodontitis in adult whites: a systematic review and meta-analysis. J Periodontol 2012; 83: 1407-1419.
96. Collins JS, Perry RT, Watson B Jr etal. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am J Med Genet 2000; 96: 823-830.
97. Song GG, Choi SJ, Ji JD, Lee YH. Association between tumor necrosis factor-α promoter -308 A/G, -238 A/G, interleukin-6 -174 G/C and -572 G/C polymorphisms and periodontal disease: a meta-analysis. Mol Biol Rep 2013; 40: 5191-5203.
98. Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y. Tumour necrosis factor- alpha gene (TNF-alpha) -1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 2003; 30: 524-531.
99. Brett J, Schmidt AM, Yan SD etal. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699-1712.
100. Kook SY, Seok Hong H, Moon M, Mook-Jung I. Disruption of blood-brain barrier in Alzheimer disease pathogenesis. Tissue Barriers [serial on the internet]. 2013; 1: [about4. p.]. [Cited 24 May 2014.] Available from URL: https://www.landesbioscience.com/journals/tissuebarriers/2012TISSBARRIER035R.pdf.
101. Lalla E, Lamster IB, Drury S, Fu C, Schmidt AM. Hyperglycemia, glycoxidation and receptor for advanced glycation endproducts: potential mechanisms underlying diabetic complications, including diabetes-associated periodontitis. Periodontol 2000 2000; 23: 50-62.
102. Hollá LI, Kanková K, Fassmann A etal. Distribution of the receptor for advanced glycation end products gene polymorphisms in patients with chronic periodontitis: a preliminary study. J Periodontol 2001; 72: 1742-1746.
103. Altman R, Rutledge JC. The vascular contribution to Alzheimer's disease. Clin Sci (Lond) 2010; 119: 407-421.
104. Ghizoni JS, Taveira LA, Garlet GP etal. Increased levels of Porphyromonas gingivalis are associated with ischemic and hemorrhagic cerebrovascular disease in humans: an in vivo study. J Appl Oral Sci 2012; 20: 104-112.
105. Karnoutsos K, Papastergiou P, Stefanidis S, Vakaloudi A. Periodontitis as a risk factor for cardiovascular disease: the role of anti-phosphorylcholine and anti-cardiolipin antibodies. Hippokratia 2008; 12: 144-149.
106. Beck JD, Slade G, Offenbacher S. Oral disease, cardiovascular disease and systemic inflammation. Periodontol 2000 2000; 23: 110-120.
107. Erickson PR, Herzberg MC. The Streptococcus sanguis platelet aggregation-associated protein. Identification and characterization of the minimal platelet-interactive domain. J Biol Chem 1993; 268: 1646-1649.
108. Notani H, Inoue Y, Sugano N, Jibiki M, Umeda M, Izumi Y. Whole-blood platelet aggregation by Porphyromonas gingivalis in patients with peripheral arterial disease. J Med Dent Sci 2011; 58: 7-14.
109. Bush AI, Martins RN, Rumble B etal. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 1990; 265: 15977-15983.
110. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995; 213: 96-103.
111. Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol 1999; 56: 1449-1452.
112. Berr C, Balansard B, Arnaud J, Roussel AM, Alpérovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Artériel. J Am Geriatr Soc 2000; 48: 1285-1291.
113. Cervellati C, Cremonini E, Bosi C etal. Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease. Curr Alzheimer Res 2013; 10: 365-372.
114. Bullon P, Newman HN, Battino M. Obesity, diabetes mellitus, atherosclerosis and chronic periodontitis: a shared pathology viaoxidative stress and mitochondrial dysfunction? Periodontol 2000 2014; 64: 139-153.
115. Drisko CH. Nonsurgical periodontal therapy. Periodontol 2000 2001; 25: 77-88.
116. Cudaback E, Jorstad NL, Yang Y, Montine TJ, Keene CD. Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol 2014; 88: 565-572.
117. Strohmeyer R, Kovelowski CJ, Mastroeni D, Leonard B, Grover A, Rogers J. Microglial responses to amyloid beta peptide opsonization and indomethacin treatment. J Neuroinflammation [serial on the internet]. 2005 [cited 2014 May 27]; 2: [about11. p.]. Available from: http://www.jneuroinflammation.com/content/2/1/18.
118. Rogers J, Kirby LC, Hempelman SR etal. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
119. Nivsarkar M, Banerjee A, Padh H. Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Pharmacol Rep 2008; 60: 692-698.
120. Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA, MIRAGE Study Group. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr [serial on the internet]. 2005; 5: [about6 p.]. [Cited 27 May 2014.] Available from URL: http://www.biomedcentral.com/1471-2318/5/2.
121. Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontol 2005; 32 (Suppl 6): 108-129.
122. Hewett SJ, Silakova JM, Hewett JA. Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration. J Pharmacol Exp Ther 2006; 319: 1219-1224.
123. Aisen PS, Schafer KA, Grundman M etal. Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-2826.
124. Reines SA, Block GA, Morris JC etal. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
125. ADAPT Research Group, Martin BK, Szekely C etal. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65: 896-905.
126. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1711.
127. Finckh A, Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann Intern Med 2005; 142: 212-214.
128. Fracon RN, Teófilo JM, Satin RB, Lamano T. Prostaglandins and bone: potential risks and benefits related to the use of nonsteroidal anti-inflammatory drugs in clinical dentistry. J Oral Sci 2008; 50: 247-252.
129. Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation [serial on the internet]. 2008; 5: [about 3 p.]. [Cited 30 May 2014.] Available from URL: http://www.jneuroinflammation.com/content/5/1/3.
130. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease disease following perispinal etanercept administration. J Neuroinflammation [serial on the internet]. 2008; 5:[about 10 p.]. [Cited 30 May 2014.] Available from URL: http://www.jneuroinflammation.com/content/5/1/2.
131. Elavarasu S, Sekar S, Murugan T. Host modulation by therapeutic agents. J Pharm Bioallied Sci 2012; 4: S256-S259.
132. Lalla E, Lamster IB, Feit M etal. Blockade of RAGE suppresses periodontitis associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-1124.
133. Stewart R, Weyant RJ, Garcia ME etal. Adverse oral health and cognitive decline: the health, aging and body composition study. J Am Geriatr Soc 2013; 61: 177-184.